Erratum: Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer (Journal of Clinical Oncology (2016) DOI: 10.1200/JCO.2016.67.6601);Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 31, 2016, Pages 3740-3748

  Reck, Martin ^a   Luft, Alexander ^a   Szczesna, Aleksandra ^a   Havel, Libor ^a   Kim, Sang We ^a   Akerley, Wallace ^a   Pietanza, Maria Catherine ^a   Wu, Yi Long ^a   Zielinski, Christoph ^a   Thomas, Michael ^a   Felip, Enriqueta ^a   Gold, Kathryn ^a   Horn, Leora ^a   Aerts, Joachim ^a   Nakagawa, Kazuhiko ^a   Lorigan, Paul ^a   Pieters, Anne ^a   Sanchez, Teresa Kong ^a   Fairchild, Justin ^a   Spigel, David ^a  

^a LungenClinic Grosshansdorf ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; HEMOGLOBIN; IPILIMUMAB; LACTATE DEHYDROGENASE; PLACEBO; ANTINEOPLASTIC AGENT;

ADRENAL INSUFFICIENCY; ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; COLITIS; CONTROLLED STUDY; DECREASED APPETITE; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENTEROCOLITIS; EXTENSIVE STAGE SMALL CELL LUNG CANCER; FATIGUE; FEMALE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; LEUKOCYTE COUNT; LEUKOPENIA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMALL CELL LUNG CANCER; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; CHEMICALLY INDUCED; CLINICAL TRIAL; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; NEUTROPENIA; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DIARRHEA; ETOPOSIDE; FEMALE; HUMANS; IPILIMUMAB; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84993940004     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.19.02803     Document Type: Erratum

References (51)

1. Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med 359:1367-1380, 2008 D
2. van Meerbeeck JP, Fennell DA, De Ruysscher K: Small-cell lung cancer. Lancet 378:1741-1755, 2011
3. Byers LA, Rudin CM: Small cell lung cancer: Where do we go from here? Cancer 121:664-672, 2015
4. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282-291, 1992
5. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Small cell lung cancer (version 1). https://www.nccn.org/professionals/physician-gls/pdf/sclc.pdf
6. Früh M, De Ruysscher D, Popat S, et al: Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi99-vi105, 2013 (suppl 6)
7. Lebeau B, Chastang C, Allard P, et al: Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: Definitive results of a randomized clinical trial-The "Petites Cellules" Group. Eur Respir J 5:286-290, 1992
8. Lara PN Jr, Natale R, Crowley J, et al: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530-2535, 2009
9. Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001
10. Lally BE, Urbanic JJ, Blackstock AW, et al: Small cell lung cancer: Have we made any progress over the last 25 years? Oncologist 12:1096-1104, 2007
11. Oze I, Hotta K, Kiura K, et al: Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: Disappointing results. PLoS One 4:e7835, 2009
12. Peifer M, Ferńandez-Cuesta L, Sos ML, et al: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104-1110, 2012
13. Darnell RB: Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 93:4529-4536, 1996
14. Koyama K, Kagamu H, Miura S, et al: Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 14:6770-6779, 2008
15. Antonia SJ, Ló pez-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 10.1016/S1470-2045(16)30098-5 [epub ahead of print on June 3, 2016]
16. Ott PA, Elez Fernandez ME, Hiret S, et al: Pembrolizumab for extensive-stage SCLC: Efficacy and relationship with PD-L1 expression. Presented at the 16thWorld Conference on Lung Cancer, Denver, CO, September 6-9, 2015 (abstr 3285)
17. Reck M, Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:75-83, 2013
18. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
19. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
20. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012
21. Spigel DR, Socinski MA: Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol 8:587-598, 2013
22. Jure-Kunkel M, Masters G, Girit E, et al: Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol Immunother 62:1533-1545, 2013
23. Lynch TJ, Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046-2054, 2012
24. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
25. O'Day SJ, Maio M, Chiarion-Sileni V, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-Arm phase II study. Ann Oncol 21: 1712-1717, 2010
26. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164, 2010
27. Weber J, Thompson JA, Hamid O, et al: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administeredwith or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598, 2009
28. Tarhini AA, Edington H, Butterfield LH, et al: Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705, 2014
29. Meyer C, Cagnon L, Costa-Nunes CM, et al: Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63:247-257, 2014
30. Martens A, Wistuba-Hamprecht K, Foppen MG, et al: Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22:2908-2918, 2016
31. Santegoets SJ, Stam AG, Lougheed SM, et al: Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer 2:31, 2014
32. Tian T, Gu X, Zhang B, et al: Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark 15:425-432, 2015
33. Zhou T, Zhan J, Hong S, et al: Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 5:10481, 2015
34. Ilie M, Hofman V, Long E, et al: PD-L1 expression in primary tumor and circulating tumor cells in patients with small cell lung carcinomas. Presented at the American Association of Cancer Research, New Orleans, LA, April 16-20, 2016 (abstr 2220)
35. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-Term safety of nivolumab (antiprogrammed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004-2012, 2015
36. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. N Engl J Med 373: 1627-1639, 2015
37. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015
38. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
39. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015
40. Motzer RJ, Rini BI, McDermott DF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33: 1430-1437, 2015
41. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015
42. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
43. Ribas A, Puzanov I, Dummer R, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 16:908-918, 2015
44. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
45. Fehrenbacher L, Spira A, Ballinger M, et al: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837-1846, 2016
46. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-Arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
47. Antonia S, Goldberg SB, Balmanoukian A, et al: Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol 17: 299-308, 2016
48. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
49. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017, 2015
50. Rizvi NA, Gettinger SN, Goldman JW, et al: Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). J Thoracic Oncol 10:S176, 2015 (suppl 2; oral 02.05)
51. Reck M, Heigener D, Reinmuth N: Immunotherapy for small-cell lung cancer: Emerging evidence. Future Oncol 12:931-943, 2016